T. Rowe Price Associates
DFTX

T. Rowe Price Associates’s Definium Therapeutics DFTX Stock Holding History

T. Rowe Price Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Buy
70,001
+17,771
+34% +$302K ﹤0.01% 2004
2025
Q4 		$700K Buy
52,230
+11,025
+27% +$136K ﹤0.01% 2244
2025
Q3 		$486K Buy
41,205
+4,874
+13% +$45.5K ﹤0.01% 2365
2025
Q2 		$236K Buy
36,331
+5,386
+17% +$35.4K ﹤0.01% 2638
2025
Q1 		$182K Sell
30,945
-368
-1% -$2.64K ﹤0.01% 2681
2024
Q4 		$218K Buy
31,313
+8,361
+36% +$57.5K ﹤0.01% 2642
2024
Q3 		$131K Hold
22,952
– – ﹤0.01% 2768
2024
Q2 		$0 Buy
+22,952
New +$201K ﹤0.01% 2986
2022
Q2 		– Sell
-1,966
Closed -$33K – 2995
2022
Q1 		$33K Buy
1,966
+434
+28% +$7.53K ﹤0.01% 2944
2021
Q4 		$32K Sell
1,532
-387
-20% -$12.4K ﹤0.01% 2950
2021
Q3 		$67K Buy
1,919
+66
+4% +$2.85K ﹤0.01% 2890
2021
Q2 		$96K Buy
+1,853
New +$97.3K ﹤0.01% 2853

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates's DFTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Definium Therapeutics (DFTX) stake by 34% in Q1 2026, buying an estimated $302K and bringing the position to 70,001 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

T. Rowe Price Associates first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • T. Rowe Price Associates held 70,001 shares of Definium Therapeutics worth $1.32M as of Q1 2026.
  • T. Rowe Price Associates bought 17,771 Definium Therapeutics shares in Q1 2026, an estimated $302K.
  • Definium Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2004 holding.
  • T. Rowe Price Associates first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.